Skip to main content
SpringerLink
Log in

bDMARD sequences not cost effective for RA in England

  • Clinical study
  • Published:
PharmacoEconomics & Outcomes News

This is a preview of subscription content, log in via an institution to check access.

Access this article

Log in via an institution

Price excludes VAT (USA)
Tax calculation will be finalised during checkout.

Instant access to the full article PDF.

Institutional subscriptions

Reference

  • Stevenson MD, et al. The Cost-effectiveness of Sequences of Biological Disease-modifying Antirheumatic Drug Treatment in England for Patients with Rheumatoid Arthritis Who Can Tolerate Methotrexate. The Journal of Rheumatology : 15 Feb 2017. Available from: URL: http://doi.org/10.3899/jrheum.160941

Download references

Rights and permissions

Reprints and permissions

About this article

Check for updates. Verify currency and authenticity via CrossMark

Cite this article

bDMARD sequences not cost effective for RA in England. PharmacoEcon Outcomes News 773, 9 (2017). https://doi.org/10.1007/s40274-017-3794-1

Download citation

  • Published:

  • Issue Date:

  • DOI: https://doi.org/10.1007/s40274-017-3794-1

Search

Navigation